echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 1.3 billion "Thunderbolt" of pharmaceutical enterprises! Seven companies lost two or more than 1 billion yuan this year

    1.3 billion "Thunderbolt" of pharmaceutical enterprises! Seven companies lost two or more than 1 billion yuan this year

    • Last Update: 2019-12-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Haizheng pharmaceutical announced that it would withdraw 1.317 billion yuan for impairment of various assets and reduce the company's net profit this year accordingly Data shows that Haizheng pharmaceutical has more than 30000 shareholders, many of whom are well-known institutions According to statistics, by the end of December 16, 39 A-share pharmaceutical companies had disclosed the 2019 performance forecast, more than 50% of which were expected to be happy, and the estimated net profit of Cr 39 was more than 2 billion yuan; 4 pharmaceutical companies turned losses into profits, St Guanfu was the biggest loss maker of pharmaceutical stocks last year, from a huge loss of 2.7 billion yuan to a profit of 900 million yuan; and Xinbang pharmaceutical from a loss of nearly 1.3 billion yuan to a profit of more than 200 million yuan In addition, seven companies suffered the first loss, including St Jesuit, innovative medical, and Asia Pacific pharmaceutical, of which the net profit of St Jesuit and innovative medical may be over 1 billion Performance forecast of A-share pharmaceutical enterprises in 2019 Among the four pharmaceutical companies turning losses, St Guanfu was the biggest loss maker of pharmaceutical stocks last year, from a huge loss of 2.7 billion yuan to a profit of 900 million yuan; Xinbang pharmaceutical from a loss of nearly 1.3 billion yuan to a profit of more than 200 million yuan In addition, Tailong pharmaceutical and Tianmu pharmaceutical are also expected to turn losses into profits St Guanfu's first net profit loss last year was 2.712 billion yuan, a year-on-year decrease of 1060% It became a large loss account of A-share pharmaceutical enterprises, mainly due to the company's non recurring gains and losses such as provision for bad debts, estimated liabilities and goodwill impairment In the first three quarters of 2019, the net profit reached 641 million yuan; it is estimated that the net profit for the whole year is 750-900 million yuan, an increase of 127.65% - 133.18% year on year For turning losses into profits, St Guanfu said that the first is the steady growth of the company's business; the second is the earnings from equity transfer of the holding subsidiary nengte technology to the subsidiary yimante; the third is the reconciliation of the company's controlling shareholders' violations and external guarantees involving the company's litigation cases, and the expenses and losses in the early period are reversed in accordance with the relevant accounting standards Xinbang pharmaceutical is expected to make a net profit of 220-270 million yuan this year, an increase of 116.97% - 120.82% year on year The loss in 2018 is mainly due to the impairment of goodwill, which is affected by the change of peptide customers' own business and the market competition of diagnostic reagents Therefore, the impairment of goodwill is RMB 1.537 billion Among the pharmaceutical companies that have disclosed the performance forecast, 7 have suffered the first loss, including shengjitang, innovative medical, Asia Pacific pharmaceutical, etc., of which, the net profit of shengjitang and innovative medical has lost or exceeded 1 billion In addition, Qianshan Pharmaceutical Machinery Co., Ltd is expected to continue to lose its net profit in 2019 Recently, the company announced that it may be forced to delist due to major violations Shengjitang expects a net profit loss of 1.724 billion yuan in 2019, a year-on-year decrease of 965.97% Shengjitang said that the sharp decline in performance was mainly due to adverse factors such as the decline in the price of main products of the chemical business and the difficulty of recovery in the short term, changes in the supply structure of raw materials and coal, etc in the third quarter, the company made an impairment provision of 1.649 billion yuan for the production equipment and related assets of Tongzi chemical, a wholly-owned subsidiary of Tongzi chemical, which resulted in an impairment provision of 3.03 billion yuan in 2019 The quarterly net profit changed from profit to loss, with a loss of 1.674 billion yuan, down 982.76% year on year According to the data, the predecessor of St Jesuit is listed company Chi Tianhua In 2014, Guizhou shengjitang Pharmaceutical Co., Ltd (hereinafter referred to as shengjitang pharmaceutical) indirectly controlled Chitianhua by transferring its shares in the parent company of Chitianhua through an agreement In 2016, Chitianhua issued shares to purchase shengjitang pharmaceutical, adding pharmaceutical and pharmaceutical business on the basis of existing chemical fertilizer business In 2018, the name of the listed company was changed to shengjitang At the same time, the net profit of that year reached the highest value of 199 million yuan in nearly a decade, a year-on-year increase of 442% Innovative medical is expected to lose 1.1-900 billion yuan of net profit in 2019, a year-on-year decrease of 3806.55% - 3132.63% Innovative medical said that the company expected a large loss in operating performance in 2019 compared with last year, mainly because the operating conditions of its wholly-owned subsidiaries Jianhua hospital and Futian hospital were far less than expected Since the third quarter, Kanghua hospital, a wholly-owned subsidiary, has been putting into use the inpatient building of the second phase of Kanghua hospital construction project due to the increase of reserve personnel and the investment of raised funds, resulting in a significant increase in operating costs, Considering the fact that the utilization rate of beds has not been saturated after the expansion of Kanghua hospital, the company expects to withdraw about 900 million yuan of goodwill impairment loss this year In addition, the case of financial leasing dispute between Jianhua hospital and Baoxin international has not yet been decided by Shaanxi Higher People's court, and the company has accrued large amount of estimated liabilities for the above matters Qianshan Pharmaceutical Machinery Co., Ltd is expected to continue to lose its net profit in 2019 First, due to the debt crisis and limited assets, the company's production and sales of pharmaceutical machinery declined sharply Second, due to the lack of funds, the company failed to pay its debts on time, and the accrued interest, overdue interest increase and default interest increased Third, the receivables received less, the aging of accounts increased, and the accrued impairment loss increased Recently, Qianshan Pharmaceutical Machinery Co., Ltd received the notice of administrative punishment and market prohibition issued by the CSRC, and determined that the company's net profit for four consecutive years from 2015 to 2018 was actually negative, which touched on the regulations of major illegal compulsory delisting, and the company's shares may be subject to major illegal compulsory delisting It is understood that in 2015-2016 annual report of Qianshan Pharmaceutical Machinery Co., Ltd., there were virtual decrease of accounts receivable, bad debt provision, virtual increase of profits, etc., with the total virtual increase of profits in two years exceeding 400 million yuan; in 2017, there were violations of credit and information technology This is the third company that may be forced to delist in violation of major laws after Changsheng biology and kangdexin According to the data, in the evening of January 29 this year, more than 60 listed companies reported losses, of which 16 had a loss of more than 1 billion yuan, which were basically the first losses It is worth noting that most of the pharmaceutical enterprises with the first loss of performance forecast are "Thunderbolt" before the Spring Festival In the same period of 2018, no pharmaceutical enterprise has the first loss of performance forecast Some insiders said that the huge loss is generally caused by three factors: one is the large impairment of goodwill, the other is the provision of bad debts, and the third is the huge loss of the project, of which goodwill impairment is the most common Many listed companies are planted on goodwill Behind almost every company with "Thunderbolt" performance, they are all left by the crazy high premium M & A in recent years, and even some companies have greatly revised the performance forecast.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.